Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of

More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatment New patent granting adding to portfolio of 310 granted patents in 16 patent
View HTML
Toggle Summary ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET          Progress towards  seeking   approval  of  eryaspase  for the   treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase ; Fast   Track designation granted; submission of BLA
View HTML
Toggle Summary ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France) , November 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue 10)
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Jan 5 - Jan 7, 2022

LifeSci Partners 11th Annual Corporate Access Event

Summary Toggle Jan 10 - Jan 13, 2022

H.C. Wainwright, BioConnect Conference

Summary Toggle Jan 10 - Jan 13, 2022

J.P. Morgan HealthCare Conference, San Francisco

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top